Bench-Top System Streamlines Chromatography Operations
The ÄKTA pilot 600 from GE Healthcare is a lightweight bench-top chromatography system suited to streamline both GMP and non-GMP everyday operations.
The ÄKTA pilot 600 from GE Healthcare is a lightweight bench-top chromatography system suited to streamline both GMP and non-GMP everyday operations. The instrument’s modular design allows for functionality to be added or removed as user requirements change. The flow and pressure range support both production of technical batches and scale-up studies as well as small-scale production of GMP-grade material. The interactive process picture enables changes to be made in real-time, and deviations are quickly identified. The accuracy and range of the pumps facilitates precise gradient formation that supports a column sizes range of 26 to 200 mm i.d.
The system works with the company’s AxiChrom chromatography columns through the intelligent packing function and the packing port. Prepacked 1- and 2.5-L ReadyToProcess columns can also be used with the system.The compact design allows for easy movement and placement on a lab bench or a ReadyKart mobile station, with all functional parts placed on one side of the instrument for convenient access.
Source: GE Healthcare
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
